Peptide Biologix
Compound index
The atlas

Melanotan-2 (MT-II): Comprehensive Research Monograph

Synthetic cyclic lactam heptapeptide α-MSH(4–10) analogue (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2; 1024.18 g/mol) and non-selective agonist at melanocortin receptors MC1R, MC3R, MC4R, and MC5R.

Engraved cross-section of layered stone with a small green mineral seam
Plate 19Melanotan 2
Compound Monograph · Class V: Reproductive & Melanocortin
Primary Structure (Cyclic Lactam Heptapeptide) Ac-Nle1-cyclo[Asp2-His3-D-Phe4-Arg5-Trp6-Lys7]-NH2 (β-CO–ε-NH Lactam Bridge)

1. Overview and Compound Classification

Melanotan-2 (MT-II) is a synthetic cyclic heptapeptide analogue of α-melanocyte-stimulating hormone (α-MSH) developed at the University of Arizona during the 1980s and 1990s by Victor Hruby, Mac Hadley, Robert Dorr, and Norman Levine [PubMed: 16412534; PubMed: 7658432]. Whereas native α-MSH (13 amino acids) undergoes rapid proteolytic degradation in vivo with a plasma half-life of only a few minutes, MT-II truncates the peptide to its active heptapeptide core (corresponding to residues 4–10 of α-MSH) and introduces three key structural modifications: replacement of Met4 with norleucine (Nle), inversion of L-Phe7 to D-Phe, and covalent cyclization via an isopeptide lactam bridge between the β-carboxyl group of Asp and the ε-amino group of Lys.

These modifications lock the core melanocortin pharmacophore (His-D-Phe-Arg-Trp) into a stable reverse β-turn conformation, increasing potency relative to native α-MSH while conferring marked resistance to serum exopeptidases and endopeptidases. Unlike the linear analogue Melanotan-I (NDP-α-MSH, afamelanotide), which acts predominantly on peripheral MC1R receptors, the smaller, more compact cyclic structure of MT-II crosses the blood-brain barrier to activate central MC3R and MC4R receptors in the hypothalamus and brainstem. Notably, replacement of the C-terminal carboxamide of MT-II with a free carboxylic acid (-OH) yielded PT-141 (bremelanotide).

2. Chemical Structure and Molecular Properties

Melanotan-2 has the systematic chemical structure N-acetyl-L-norleucyl-cyclo(L-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-lysinamide). The intramolecular lactam bond between Asp and Lys forms a macrocyclic ring encompassing the sequence Asp-His-D-Phe-Arg-Trp-Lys.

Table 1: Physicochemical Properties of Melanotan-2
Property Value
Amino Acid Sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2
Molecular Formula C50H69N15O9
Molecular Weight 1024.18 g/mol
CAS Registry Number 121062-08-6
Peptide Type Cyclic heptapeptide
Cyclization Lactam bridge between Asp4 and Lys10 (α-MSH numbering)
Stereochemistry Contains D-Phe at position 7 (α-MSH numbering)
Solubility Water soluble (as acetate salt)
LogP -0.42 (calculated)
pKa ~12.5 (guanidinium group)

2.1 Rationale of Structural Modifications

  • Norleucine Substitution (Nle): Replaces native Met4 of α-MSH with the isosteric aliphatic side chain of norleucine, providing resistance to enzymatic oxidation that rapidly degrades methionine-containing peptides in biological systems.
  • D-Phenylalanine Inversion (D-Phe): Substitution of D-phenylalanine at position 7 introduces stereochemical constraints that protect against proteolytic cleavage while maintaining the essential pharmacophore geometry required for receptor activation.
  • Asp–Lys Lactam Macrocyclization: The lactam bridge between aspartic acid and lysine residues enforces a constrained β-turn conformation that pre-organizes the peptide structure for optimal receptor binding, while N-terminal acetylation and C-terminal amidation protect the peptide from exopeptidase degradation [PubMed: 7658432].

3. Mechanism of Action and Receptor Pharmacology

Melanotan-2 functions as a non-selective agonist at melanocortin receptors, exhibiting activity across multiple receptor subtypes within this G-protein-coupled receptor family [PubMed: 1516719; PubMed: 15856065]. The compound demonstrates high affinity for MC1R, MC3R, MC4R, and MC5R, while showing minimal activity at MC2R (Ki > 1 μM), establishing approximately 1000-fold selectivity for MC1R versus MC2R. Upon binding, MT-II promotes coupling to Gαs proteins, resulting in adenylyl cyclase activation, elevation of intracellular cyclic AMP (cAMP), and activation of protein kinase A (PKA) and CREB.

Table 2: Melanocortin Receptor Binding Profile
Receptor Subtype Ki (nM) EC50 (nM) Primary Tissue Distribution Physiological Effects
MC1R 0.23 0.12 Melanocytes, keratinocytes Melanogenesis, pigmentation
MC2R >1000 >1000 Adrenal cortex Steroidogenesis (minimal activity)
MC3R 0.31 0.27 CNS, peripheral tissues Energy homeostasis, inflammation
MC4R 0.19 0.11 Hypothalamus, brainstem Appetite regulation, sexual function
MC5R 0.72 0.58 Exocrine glands, peripheral tissues Sebaceous secretion, thermoregulation

3.1 Peripheral Melanogenesis (MC1R) and Pharmacokinetics

In epidermal melanocytes, PKA-dependent phosphorylation of CREB upregulates transcription of tyrosinase, tyrosinase-related protein-1 (TRP-1), and tyrosinase-related protein-2 (TRP-2), stimulating eumelanin synthesis, melanosome maturation, and transfer to surrounding keratinocytes. Following subcutaneous administration, Melanotan-2 exhibits a Tmax of approximately 1–2 hours, estimated bioavailability of 80–90% relative to intravenous administration, and a plasma elimination half-life of 33–40 minutes, with elimination occurring primarily through renal excretion.

3.2 Central Neuroendocrine and Metabolic Circuits (MC3R / MC4R)

Within the central nervous system, MT-II activates MC4R and MC3R neurons in the paraventricular nucleus and arcuate nucleus of the hypothalamus, modulating pro-opiomelanocortin (POMC) and agouti-related peptide (AgRP) circuits that regulate energy balance, feeding behavior, and sexual function via nitric oxide and autonomic signaling pathways [PubMed: 15856065; PubMed: 11805404].

4. Preclinical Research and Animal Studies

In preclinical animal and cellular models, Melanotan-2 has been characterized across melanogenesis, metabolic regulation, sexual behavior, and toxicology paradigms:

  • Animal Models of Pigmentation: In C57BL/6 mice and rodent models, subcutaneous administration of MT-II (0.1 to 1.0 mg/kg) produced dose-dependent increases in skin pigmentation, with visible darkening within 24–48 hours, maximal effects at 5–7 days post-administration, and duration of 2–4 weeks following a single dose.
  • Metabolic and Anorectic Effects: In diet-induced obese (DIO) rats, chronic subcutaneous administration of MT-II (0.5–2.0 mg/kg once daily) produced 30–50% reductions in food intake and 15–25% body weight loss over 4-week treatment periods, accompanied by increased energy expenditure and improved glucose homeostasis; pharmacological blockade or genetic deletion of MC4R abolished these effects.
  • Sexual Function and Inflammation Studies: In male rats, MT-II (0.1–1.0 mg/kg SC) enhanced erectile function, reduced mount and intromission latencies, and increased sexual motivation. Through MC1R and MC3R activation on immune cells, MT-II also attenuates inflammatory cytokine production [PubMed: 15001661].
  • Toxicological Studies: Acute LD50 values in mice and rats exceeded 100 mg/kg SC or IV, with negative Ames and chromosomal aberration genotoxicity assays; repeated-dose studies (28-day and 90-day) identified transient nausea, reduced food intake at doses >2 mg/kg/day, and modest sympathetic increases in blood pressure and heart rate.
Table 3: Summary of Key Preclinical Findings Literature summary of published toxicology findings.
Study Type Model System Dose Range Primary Findings
Receptor Binding Recombinant cell lines 0.01–100 nM High affinity for MC1R, MC3R, MC4R, MC5R; minimal MC2R activity
Melanogenesis C57BL/6 mice 0.1–1.0 mg/kg SC Dose-dependent pigmentation; maximal at 5–7 days; duration 2–4 weeks
Metabolic Effects DIO rats 0.5–2.0 mg/kg SC 30–50% reduction in food intake; 15–25% body weight loss; improved glucose homeostasis
Sexual Function Male rats 0.1–1.0 mg/kg SC Enhanced erectile function; reduced latencies; increased sexual motivation
Acute Toxicity Rodents LD50 >100 mg/kg Low acute toxicity; primary effects: nausea, anorexia

5. Human Studies and Clinical Trials

5.1 Phase I Safety and Pharmacokinetic Studies

Initial human studies with Melanotan-2 in small cohorts of healthy volunteers evaluated subcutaneous single ascending doses and short multi-dose courses [PubMed: 8637402; PubMed: 1942429]. Peak plasma concentrations were achieved at 60–90 minutes post-injection, with a human plasma elimination half-life of approximately 33 minutes, though biological effects persisted substantially longer. Reported adverse effects were dose-dependent and included nausea (occurring in 60–80% of subjects at higher doses), facial flushing, stretching and yawning behavior, spontaneous erections in male subjects, and transient sympathetic elevations in systolic blood pressure (mean increase 8–12 mmHg) and heart rate (mean increase 10–15 bpm).

5.2 Pigmentation and Photoprotection Studies

Clinical investigations of melanogenic properties in subjects with fair skin phototypes I–III demonstrated significant skin darkening by reflectance spectrophotometry, with melanin indices increasing 40–150% from baseline depending on initial skin type and study regimen. Minimal erythema dose (MED) testing before and after treatment courses revealed post-treatment MED values typically 2–3 times higher than baseline. However, researchers noted that the induced pigmentation provided incomplete protection against UV damage, and subjects still experienced sunburn with sufficient UV exposure, demonstrating that MT-II-induced pigmentation does not prevent UV-induced erythema or DNA damage under higher UV exposure.

5.3 Erectile Dysfunction and Female Sexual Dysfunction Trials

In a randomized, double-blind, placebo-controlled crossover study in 20 men with psychogenic erectile dysfunction [PubMed: 9679884], 60–80% of subjects reported adequate erections following MT-II compared to 20–30% with placebo (p < 0.01). A subsequent trial in men with organic ED of mixed etiology (vasculogenic, neurogenic, and diabetic) showed improvements in 40–55% of subjects versus 15–25% with placebo, with onset at 30–60 minutes and duration of 4–8 hours. Exploratory randomized controlled research in 32 premenopausal women with hypoactive sexual desire disorder (HSDD) reported improvements in Female Sexual Function Index (FSFI) desire, arousal, and satisfaction domains alongside increased genital blood flow by vaginal photoplethysmography, accompanied by nausea in approximately 70% of sessions.

5.4 Limitations of Clinical Development

Despite encouraging early-phase findings [PubMed: 16412534], formal clinical development of Melanotan-2 as a pharmaceutical agent was discontinued due to the high incidence of nausea, non-selective melanocortin receptor activation, potential cardiovascular risks with chronic administration, and the lack of long-term safety data regarding melanocytic lesions and melanoma risk [PubMed: 36537241].

6. Analytical Characterization and Quality Control

6.1 High-Performance Liquid Chromatography and Method Validation

Reversed-phase HPLC represents the primary analytical technique for purity assessment and quantification of Melanotan-2 in both reference preparations and biological samples. Typical methods employ C18 columns (4.6 × 150–250 mm, 5 μm particle size) with gradient elution from 20% to 40% acetonitrile in water containing 0.1% trifluoroacetic acid over 30 minutes and UV detection at 214 nm (peptide bond absorption) or 280 nm (aromatic amino acid absorption), with MT-II typically eluting at 18–22 minutes. Quantification requires preparation of calibration curves using authenticated reference standards across concentration ranges appropriate for the application (typically 10–1000 μg/mL for purity analysis and 0.1–10 μg/mL for biological samples). Method validation parameters established according to ICH guidelines include linearity (r2 > 0.999), precision (RSD < 2% for replicate injections), accuracy (recovery 95–105%), limit of detection (LOD ~0.05 μg/mL), and limit of quantification (LOQ ~0.15 μg/mL).

6.2 Mass Spectrometry, Amino Acid Analysis, and Peptide Mapping

Electrospray ionization mass spectrometry (ESI-MS) in positive mode generates predominantly doubly-charged ions [M+2H]2+ at m/z 512.6 and triply-charged ions [M+3H]3+ at m/z 342.1, with the monoisotopic molecular ion [M+H]+ at m/z 1024.5 serving as the primary confirmatory signal in HRMS. LC-MS/MS methods operating in SRM/MRM mode monitor characteristic immonium ion transitions (m/z 512.6 → 136.1 for Trp, 512.6 → 110.1 for His, and 512.6 → 120.1 for Phe), achieving pg/mL detection limits in biological matrices. Complete acid hydrolysis (6 N HCl, 110°C, 24 hours under vacuum) followed by amino acid analysis verifies the 1:1:1:1:1:1:1 molar stoichiometry of Nle:Asp:His:Phe:Arg:Trp:Lys, while chiral HPLC confirms D-Phe stereochemical purity and stability-indicating HPLC methods separate Trp/Nle oxidation products, deamidated species, and lactam ring-hydrolysis degradants.

Table 4: Comparative Analytical Methods for Melanotan-2
Method Application Detection Limit Key Advantages Limitations
RP-HPLC-UV Purity, quantification 0.05–0.15 μg/mL Rapid, reproducible, cost-effective Cannot distinguish isomers or sequence variants
LC-MS/MS Identity, quantification in biological matrices 0.001–0.01 ng/mL High sensitivity and selectivity Requires specialized instrumentation, matrix effects
HRMS Molecular weight confirmation, impurity profiling 0.1–1.0 ng/mL Accurate mass, isotope patterns Complex data interpretation
Amino Acid Analysis Composition verification, absolute quantification 1–10 μg (total peptide) Quantitative, orthogonal to HPLC Destroys sample, cannot detect sequence errors
Peptide Mapping Sequence verification, modification detection 10–100 ng Complete sequence coverage Time-consuming, requires lactam opening & digestion

7. Research Applications and Experimental Uses

7.1 Melanocortin Receptor Pharmacology and Selectivity Screening

Melanotan-2 is the standard non-selective pan-melanocortin agonist (MC1R/MC3R/MC4R/MC5R) used in radioligand binding assays and functional GPCR cAMP/second-messenger screens to benchmark novel subtype-selective agonists and antagonists, as well as fluorescently labeled and radiometal-conjugated imaging probes.

7.2 Neurobiology of Energy Balance, Sexual Function, Pigmentation, and Inflammation

In neuroscience, endocrinology, and dermatology laboratories, MT-II is used to map hypothalamic POMC/AgRP feeding circuits, sympathetic thermogenic pathways in brown adipose tissue, central sexual arousal nuclei in the paraventricular hypothalamus, MC1R-driven eumelanogenesis in melanocytes, and MC3R/MC1R-mediated anti-inflammatory cytokine modulation.

8. Preclinical Dosing Paradigms in Research Settings

Published rodent studies have used Melanotan-2 at 0.1 to 2.0 mg/kg via subcutaneous or intraperitoneal injection (0.5–1.0 mg/kg single doses for melanogenesis; 0.5–2.0 mg/kg daily for metabolic/feeding studies; 0.1–0.5 mg/kg acute doses 30–60 minutes prior to sexual behavior testing). Because MT-II exhibits a prolonged pharmacodynamic duration relative to native α-MSH, crossover animal experiments incorporate washout intervals of at least 7–14 days, and feeding/metabolic protocols frequently include pair-fed vehicle control groups to separate direct melanocortin receptor effects from secondary consequences of reduced caloric intake.

9. Storage and Stability

Lyophilized Melanotan-2 acetate salt maintains ≥95% purity for at least 24 months when stored sealed with desiccant at −20°C or below protected from light. Primary degradation pathways involve oxidation of the indole ring of Trp and base-catalyzed hydrolysis of the lactam bridge or deamidation at elevated pH. At neutral pH (6.5–7.5) and 4°C, aqueous solutions maintain ≥90% purity for 7–14 days, whereas mildly acidic conditions (pH 4–5) extend refrigerated stability to 14–21 days; longer-term solution storage requires single-use aliquots frozen at −20°C to −80°C to avoid repeated freeze-thaw cycles.

10. Safety Profile and Risk Assessment

Both controlled Phase I/II human clinical trials and published pharmacovigilance literature document a characteristic spectrum of melanocortin-mediated adverse effects associated with Melanotan-2 [PubMed: 8637402; PubMed: 36537241]:

Table 5: Documented Adverse Effect Profile in Clinical Research
Adverse Effect Reported Incidence Severity Typical Time Course Receptor / Physiological Mechanism
Nausea & gastrointestinal discomfort 60–80% Mild to moderate 1–4 hours post-dose Central MC4R activation in area postrema and dorsal vagal complex
Facial & upper-body flushing 40–60% Mild, self-limiting 30 min – 3 hours Cutaneous vasodilation
Transient blood pressure elevation 30–50% Mild to moderate (+8–12 mmHg systolic) 1–4 hours post-dose Hypothalamic MC4R-mediated sympathetic nervous system activation
Tachycardia / heart rate increase 40–60% Mild to moderate (+10–15 bpm) 1–4 hours post-dose Central sympathetic outflow modulation
Spontaneous penile erections & yawning/stretching 70–90% (males) Expected pharmacological effect 30 min – 4 hours Central hypothalamic MC4R oxytocinergic/dopaminergic activation
Darkening of existing nevi / new melanocytic nevi 80–100% (repeated dosing) Dermatological monitoring concern Days to weeks; persists months Peripheral MC1R stimulation in epidermal and junctional melanocytes

11. Literature Review and References

Foundational medicinal chemistry by Hruby, Hadley, Dorr, and Levine established cyclic lactam constraints as a general strategy for stabilizing turn-forming peptide hormones [PubMed: 1942429; PubMed: 7658432; PubMed: 16412534]. Subsequent receptor cloning by Chhajlani and Wikberg [PubMed: 1516719] and neuroanatomical mapping by Cone [PubMed: 15856065] defined the five-receptor melanocortin family, while Catania and Lipton elucidated melanocortin control of inflammation [PubMed: 15001661].

11.1 Primary Literature References

  1. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. doi:10.1016/j.peptides.2005.01.029 [PubMed: 16412534]
  2. Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998;160(2):389-393. doi:10.1016/S0022-5347(01)62894-0 [PubMed: 9679884]
  3. Chhajlani V, Wikberg JE. Molecular cloning and expression of the human melanocyte stimulating hormone receptor cDNA. FEBS Lett. 1992;309(3):417-420. doi:10.1016/0014-5793(92)80820-7 [PubMed: 1516719]
  4. Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci. 2005;8(5):571-578. doi:10.1038/nn1455 [PubMed: 15856065]
  5. Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-1784. doi:10.1016/0024-3205(96)00160-9 [PubMed: 8637402]
  6. Hruby VJ, Lu D, Sharma SD, et al. Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5, D-Phe7,Lys10] alpha-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J Med Chem. 1995;38(18):3454-3461. doi:10.1021/jm00018a005 [PubMed: 7658432]
  7. Giuliano F, Allard J. Dopamine and male sexual function. Eur Urol. 2001;40(6):601-608. doi:10.1159/000049844 [PubMed: 11805404]
  8. Catania A, Gatti S, Colombo G, Lipton JM. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev. 2004;56(1):1-29. doi:10.1124/pr.56.1.1 [PubMed: 15001661]
  9. Levine N, Sheftel SN, Eytan T, et al. Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. JAMA. 1991;266(19):2730-2736. [PubMed: 1942429]
  10. Florentin A, Diguet L, Velazquez N, et al. Illicit use of melanotan I and II: a worldwide issue. Br J Dermatol. 2023;188(3):303-312. doi:10.1093/bjd/ljac070 [PubMed: 36537241]

13. Conclusion

Melanotan-2 represents a foundational milestone in peptide medicinal chemistry, demonstrating how side-chain-to-side-chain lactam cyclization and D-amino acid substitution transform a labile endogenous neuropeptide fragment into a metabolically stable, sub-nanomolar GPCR agonist. While non-selective receptor activation and cardiovascular/emetic side effects prevented its clinical approval, MT-II remains an indispensable pharmacological reference standard across melanocortin receptor research, neuroendocrinology, and dermatological biology.